Menadione, a vitamin K precursor, may slow prostate cancer growth in mice and human cells, targeting cancer cells by depleting lipid PI(3)P.

Research from Cold Spring Harbor Laboratory indicates that menadione, a vitamin K precursor, may slow prostate cancer growth in mice and human-derived cells. Unlike the unsuccessful vitamin E trials, menadione targets cancer cells by depleting the lipid PI(3)P, crucial for their survival. Lead researcher Lloyd Trotman plans to initiate pilot studies on human patients, with hopes of also addressing myotubular myopathy, a rare muscle growth condition in boys.

October 24, 2024
7 Articles